Loading clinical trials...
Loading clinical trials...
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Amlitelimab
Placebo
Locations
103
United States
Investigative Site Number: 1018
Fremont, California, United States
Investigative site #1022
Sacramento, California, United States
Investigative Site Number: 1006
Boca Raton, Florida, United States
Investigative Site Number: 1001
Clearwater, Florida, United States
Investigative Site Number: 1019
Coral Gables, Florida, United States
Investigative Site Number: 1007
Miami, Florida, United States
Start Date
December 13, 2021
Primary Completion Date
April 26, 2023
Completion Date
February 21, 2024
Last Updated
July 3, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Kymab Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions